SG11201706521XA - Panobinostat dosages for multiple myeloma - Google Patents

Panobinostat dosages for multiple myeloma

Info

Publication number
SG11201706521XA
SG11201706521XA SG11201706521XA SG11201706521XA SG11201706521XA SG 11201706521X A SG11201706521X A SG 11201706521XA SG 11201706521X A SG11201706521X A SG 11201706521XA SG 11201706521X A SG11201706521X A SG 11201706521XA SG 11201706521X A SG11201706521X A SG 11201706521XA
Authority
SG
Singapore
Prior art keywords
panobinostat
dosages
multiple myeloma
myeloma
panobinostat dosages
Prior art date
Application number
SG11201706521XA
Other languages
English (en)
Inventor
Rong Lin
Song Mu
Sofia Paul
Laura Grazioli
Renaud Capdeville
Florence Binlich
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55405393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201706521X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201706521XA publication Critical patent/SG11201706521XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG11201706521XA 2015-02-19 2016-02-17 Panobinostat dosages for multiple myeloma SG11201706521XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562118254P 2015-02-19 2015-02-19
US201562119571P 2015-02-23 2015-02-23
PCT/IB2016/050850 WO2016132303A1 (fr) 2015-02-19 2016-02-17 Dosages de panobinostat pour le traitement du myélome multiple

Publications (1)

Publication Number Publication Date
SG11201706521XA true SG11201706521XA (en) 2017-09-28

Family

ID=55405393

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201706521XA SG11201706521XA (en) 2015-02-19 2016-02-17 Panobinostat dosages for multiple myeloma

Country Status (19)

Country Link
US (3) US20190388393A1 (fr)
EP (1) EP3258933A1 (fr)
JP (2) JP2018507216A (fr)
KR (1) KR20170118798A (fr)
CN (1) CN107249596A (fr)
AU (2) AU2016221327A1 (fr)
BR (1) BR112017017594A2 (fr)
CA (1) CA2976755A1 (fr)
CL (1) CL2017002116A1 (fr)
IL (1) IL253895A0 (fr)
MA (1) MA41544A (fr)
MX (1) MX2017010577A (fr)
PH (1) PH12017501494A1 (fr)
RU (1) RU2729425C2 (fr)
SG (1) SG11201706521XA (fr)
TN (1) TN2017000356A1 (fr)
TW (1) TW201630602A (fr)
WO (1) WO2016132303A1 (fr)
ZA (1) ZA201705363B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110314222B (zh) * 2019-08-07 2023-05-26 上海交通大学医学院附属瑞金医院 硼替佐米和帕比司他或伏立诺他的组合物在制备治疗耐药型mll白血病的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5665271B2 (ja) * 2005-08-03 2015-02-04 ノバルティス アーゲー 骨髄腫の処置のためのｈｄａｃ阻害剤の使用
ES2570934T3 (es) 2006-06-12 2016-05-23 Novartis Ag Sales de N-hidroxi-3-[4-[[[2-(2-metil-1H-indol-3-il)etil]amino]metil]fenil]-2E-2-propenamida
BRPI0807812A2 (pt) * 2007-02-15 2020-06-23 Novartis Ag Combinações de lbh589 com outros agentes terapêuticos para tratar câncer
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
US8263578B2 (en) * 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
CN105073115A (zh) * 2013-03-14 2015-11-18 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂和cyp3a4抑制剂的组合

Also Published As

Publication number Publication date
US20230181529A1 (en) 2023-06-15
ZA201705363B (en) 2019-07-31
BR112017017594A2 (pt) 2018-05-08
US20190388393A1 (en) 2019-12-26
TW201630602A (zh) 2016-09-01
RU2729425C2 (ru) 2020-08-06
US20200093795A1 (en) 2020-03-26
MA41544A (fr) 2017-12-26
AU2016221327A1 (en) 2017-08-31
CA2976755A1 (fr) 2016-08-25
AU2019200876B2 (en) 2020-05-28
WO2016132303A1 (fr) 2016-08-25
PH12017501494A1 (en) 2018-01-29
RU2017132445A (ru) 2019-03-20
CN107249596A (zh) 2017-10-13
JP2021105048A (ja) 2021-07-26
KR20170118798A (ko) 2017-10-25
TN2017000356A1 (en) 2019-01-16
AU2019200876A1 (en) 2019-02-28
MX2017010577A (es) 2017-12-07
RU2017132445A3 (fr) 2019-09-23
EP3258933A1 (fr) 2017-12-27
IL253895A0 (en) 2017-10-31
JP2018507216A (ja) 2018-03-15
CL2017002116A1 (es) 2018-05-18

Similar Documents

Publication Publication Date Title
IL256116A (en) geometric
GB201510019D0 (en) Compounds
ZA201804618B (en) Isoindole compounds
GB201514754D0 (en) Compounds
HK1255871A1 (zh) 用於治療骨髓瘤的賽度替尼
GB201514751D0 (en) Compounds
RS61999B1 (sr) Jedinjenja
HK1249901B (zh) 用於抑制ror-gamma-t的化合物
GB201520500D0 (en) Compounds
GB201520499D0 (en) Compounds
GB201508864D0 (en) Compounds
GB201520419D0 (en) Compounds
GB201510493D0 (en) Compounds
ZA201705363B (en) Panobinostat dosages for multiple myeloma
GB201508857D0 (en) Compounds
GB201503926D0 (en) Compounds
GB201501115D0 (en) Compounds
GB201519969D0 (en) Compounds
GB201519965D0 (en) Compounds
GB201519549D0 (en) Compounds
GB201519212D0 (en) Compounds
GB201519213D0 (en) Compounds
GB201516445D0 (en) Compounds
GB201516059D0 (en) Compounds
GB201512279D0 (en) Compounds